Keith W. Pratz, MD

Keith W. Pratz Stretching a doublet into a triplet for FLT3 AML , Blood Advances, 10(17): 2026,5819-5820

Boulter AC, Li Y, Wang X, Zheng DJ, Pratz K, Luger S, Aplenc R, Getz KD. Primary Cardioprotection in Frontline Anthracycline Therapy for Adult Hematologic Cancers , JAMA Netw Open, 9(8): 2026,e2630536

Pratz KW. Humoral influence on cytotoxicity in myeloid leukemia therapies , Haematologica, 111(8): 2026,2558

Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld LC, Balasubramanian SK, Guru Murthy GS, Rotta M, Palmisiano N, McCloskey J, Saliba AN, Khawandanah M, Madanat YF, Naqvi K, Qasrawi AH, Schiller GJ, Badar T, Gojo I, Yaghmour G, Osman D, Zhang H, Tian Y, Soifer HS, Riches M, Corum D, Leoni M, Fathi AT, Issa GC. Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia , Blood: 2026,blood.2026034043.

Ambinder A, Levis M, Wang X, Pratz K, Matthews A. A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy , Leukemia Research, 164: 2026,108204.

Pratz KW, DiNardo CD, Arellano M, Thirman MJ, Pullarkat V, Becker PS, Smith BD, Zhang M, Miu K, Potluri J, Pollyea DA Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies , Am J Hematol, 101(4): 2026,926-929

Foran JM, Sun Z, Luger SM, Claxton DF, Lazarus HM, Arber DA, Rowe JM, Paietta E, Racevskis J, Garrett-Bakelman F, Zhang Y, Altman JK, Al-Kali A, Zheng H, Pratz KW, Broun ER, Powell BL, O'Dwyer KM, Godwin JE, Ofran Y, Litzow MR, Tallman MS. Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial. , Blood Neoplasia, 3(2): 2026,100194.

Anjali Advani, Li Chen, Zhuoxin Sun, Ryan Mattison, Elisabeth Paietta, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Dan Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Dimitrios Tzachanis, Pankit Vachhani, Rupali Bhave, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Selina Luger, Charles Mullighan, Martin Tallman, Mark Litzow Toxicities on the E1910 phase III randomized trial of blinatumomab plus chemotherapy in adults with BCR: ABL-1 negative acute lymphoblastic leukemia , American Society of Hematology Annual Meeting, Orlando, FL., 146: 2025

Xiaoming Zhong, Kathryn Roberts, Lindsey Montefiori, Zhuoxin Sun, Huimei Wei, Petri Polonen, Ti-Cheng Chang, Wenchao Zhang, Shaohua Lei, Evadnie Rampersaud, Yiping Fan, Gang Wu, Ryan Mattison, Yanming Zhang, Janis Racevskis, Hillard Lazarus, Jacob Rowe, Daniel Arber, Matthew Wieduwilt, Michaela Liedtke, Julie Bergeron, Brent Wood, Keith Pratz, Shira Dinner, Noelle Frey, Steven Gore, Bhavana Bhatnagar, Ehab Atallah, Geoffrey Uy, Deepa Jeyakumar, Tara Lin, Cheryl Willman, Nikolai Podoltsev, Daniel Deangelo, Shejal Patel, Michelle Elliott, Anjali Advani, Dimitrios Tzachanis, Pankit Vachhani, Rupali Roy, Elad Sharon, Richard Little, Harry Erba, Richard Stone, Martin Tallman, Jun J Yang, Elisabeth Paietta, Selina Luger, Mark Litzow, Charles Mullighan Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial , American Society of Hematology Annual Meeting, Orlando, FL., 146: 2025

James Foran, Li Chen, Selina Luger, Zhuoxin Sun, Heidi Klepin, Catherine Lai, David Claxton, Hillard Lazarus, Daniel Arber, Jacob Rowe, Elisabeth Paietta, Janis Racevskis, Francine Garrett-Bakelman, Yanming Zhang, Jessica Altman, Aref Al-Kali, Hong Zheng, Keith Pratz, Kristen O'Dwyer, Edward Broun, Bayard Powell, John Godwin, Yishai Ofran, Efrat Dotan, Mark Litzow, Martin Tallman, Lynne Wagner Prospective study of patient-reported depression, and cognitive and functional impairment, and impact on survival and induction mortality in fit adults age≥ 60 years receiving intensive chemotherapy (IC) for Acute Myeloid Leukemia (AML): Prospective geriatric assessment (GA) report from ECOG-ACRIN (EA) E2906 randomized study , American Society of Hematology, Orlando, FL., 146: 2025